Associate Medical Director

Final date to receive applications

Field of work:
Regulatory & Medical

Posting Date: 20 Feb 2026

Final date to receive applications

Location: Madison 07940, New Jersey, United States

Contract type: Permanent

Job : 4257

Your Role

The Associate Medical Director is responsible for supporting the development and execution of medical strategy and tactics for delgocitinib (Anzupgo) and its lifecycle management. This includes, primarily, new indications for which a formal indication is planned (e.g. palmoplantar pustulosis and lichen sclerosus). In addition, it includes support for other indications being studied outside of CHE e.g. as part of investigator initiated studies or research collaborations.

The individual will contribute medical/scientific expertise to core scientific affairs activities, including scientific data generation and communication, competitive landscape analysis, utilization of insights, and mapping and engagement with Key Opinion Leaders. This role will work closely with the cross‑functional medical team, including partnering closely with global medical teams to ensure alignment and that the US strategy is at the forefront across the organization.

The individual will also play a key role in implementing projects and initiatives under the guidance of senior medical leadership.

This is a hybrid role
, based out of LEO’s Madison, NJ office
.

• Build the medical strategy around lichen sclerosus as a future potential indication for Anzupgo including leading the US disease awareness and education campaign, early publication strategy, scientific communication strategy whilst also planning activities up to the potential launch for this indication.
• Acquire, maintain, and apply knowledge and expertise in relevant medical‑scientific areas in dermatology.
• Contribute to the development and execution of North America (NA) Medical Strategy and tactics for compounds in development for lichen sclerosus (LS) and palmoplantar pustulosis (PPP) as well as potential future indications.
• Support core scientific affairs activities, including scientific data generation and communication, competitive landscape analysis, utilization of insights, and mapping/engagement with Key Opinion Leaders in relevant fields – e.g. dermatology and gynaecology, and contribute to gathering and sharing competitive intelligence within the organization.
• Provide medical input into strategic and operational plans such as lifecycle, launch, brand, and global business plans, under guidance from senior medical leadership, and support LEO Pharma’s patient‑centric approach by contributing to the identification and evaluation of unmet patient needs, and assist in identifying medical marketing needs, gaps, and opportunities, and support the enhancement of scientific affairs activities.
• Participate in publication planning throughout the product lifecycle (e.g., manuscripts, congress abstracts, symposium presentations, and posters) in collaboration with local and global teams, and review documents requiring medical input—including proposals, protocols, manuscripts, posters, and standard response letters—as assigned.
• Collaborate with regulatory, pharmacovigilance, health economics, and other functions to provide medical expertise for relevant external initiatives.
• Support the organization, coordination, and facilitation of medical advisory boards, and assist in training internal and external stakeholders.
• Present medical data, where appropriate, at internal and external meetings and training sessions, and ensure that medical communications and external partner interactions are conducted appropriately and in compliance with regulations.
• Participate in the Legal Medical Review (LMR) Committee, providing medical review of assigned materials.
• Contribute to the planning and tracking of scientific affairs activities and support budget management for assigned projects.

• Minimum of 10 years of professional experience, within the pharmaceutical industry and/or in clinical practice and/or clinical research.
• Clinical experience with patients with lichen sclerosus [preferred].
• Strong pharmaceutical…